-transparent.png){kind=logo}
In real life to evaluate the effectiveness and safety of apixaban with double antiplatelet therapy for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and the recent episode of acute coronary syndrome without ST segment elevation. 8 patients with atrial fibrillation and the recent (8-14 days after the onset of symptoms of ACS) episode of acute coronary syndrome without ST segment elevation were involved into the research. The effectiveness (deaths, stroke and systemic embolism) and the safety (major clinically significant and not significant bleeding) were investigated within 3 months. There were no any strokes, systemic embolism, deaths during observational period. Nasal and mild gingival hemorrhages (not requiring medical intervention) were noted in 2 patients during the first month of treatment and two patients experienced non-permanent petechiae. Major and clinically significant bleeding was not registered. onclusions: the use of oral anticoagulant apixaban 5 mg BID or 2.5 mg BID with double antiplatelet therapy in patients with non-valvular atrial fibrillation and the recent episode of acute coronary syndrome without ST segment elevation is effective and safe for the prevention of stroke and systemic embolism during 3 months of treatment. Future researches are required.
N G Lozhkina, and
M H Hasanova, and
E A Glebchenko, and
E A Naidena, and
V A Kozik, and
A D Kuimov
June 2020,
The International journal of angiology : official publication of the International College of Angiology, Inc,
N G Lozhkina, and
M H Hasanova, and
E A Glebchenko, and
E A Naidena, and
V A Kozik, and
A D Kuimov
October 2018,
Giornale italiano di cardiologia (2006),
N G Lozhkina, and
M H Hasanova, and
E A Glebchenko, and
E A Naidena, and
V A Kozik, and
A D Kuimov
July 2020,
Deutsche medizinische Wochenschrift (1946),
N G Lozhkina, and
M H Hasanova, and
E A Glebchenko, and
E A Naidena, and
V A Kozik, and
A D Kuimov
June 2020,
Journal of clinical medicine,
N G Lozhkina, and
M H Hasanova, and
E A Glebchenko, and
E A Naidena, and
V A Kozik, and
A D Kuimov
September 2012,
Circulation,
N G Lozhkina, and
M H Hasanova, and
E A Glebchenko, and
E A Naidena, and
V A Kozik, and
A D Kuimov
November 2014,
Herz,
N G Lozhkina, and
M H Hasanova, and
E A Glebchenko, and
E A Naidena, and
V A Kozik, and
A D Kuimov
May 2010,
Circulation,
N G Lozhkina, and
M H Hasanova, and
E A Glebchenko, and
E A Naidena, and
V A Kozik, and
A D Kuimov
May 2017,
Canadian family physician Medecin de famille canadien,
N G Lozhkina, and
M H Hasanova, and
E A Glebchenko, and
E A Naidena, and
V A Kozik, and
A D Kuimov
May 2020,
The Journal of the American Osteopathic Association,
N G Lozhkina, and
M H Hasanova, and
E A Glebchenko, and
E A Naidena, and
V A Kozik, and
A D Kuimov
January 2018,
Progress in cardiovascular diseases,
